Astec LifeSciences Limited — Others, 27-01-2025: Others

Astec LifeSciences Limited has announced a board meeting in which the board approved the unaudited financial results for the quarter and nine months ended 31st December 2024. Revenue from operations is reported at ₹93.86 crore, while the net loss for the period is ₹40.40 crore. The board also re-appointed Mr. R. R. Govindan as a Non-Executive Independent Director for a second term, pending shareholder approval. Additionally, the board approved a ₹3.75 crore investment in a Special Purpose Vehicle for solar power generation, aiming for long-term renewable energy consumption. Investors might view this as a positive outlook given the focus on sustainable energy, but losses are a concern.